scholarly article | Q13442814 |
P50 | author | Bart De Strooper | Q4865062 |
Dario Alessi | Q5222818 | ||
Jinwei Zhang | Q47825457 | ||
Patrik Verstreken | Q28420142 | ||
P2093 | author name string | Diederik W Moechars | |
Guy Daneels | |||
Kristof Van Kolen | |||
Lore Delbroek | |||
Raquel da Cunha | |||
Wim Mandemakers | |||
Kris Gevaert | |||
Pieter-Jan De Bock | |||
Liesbeth Steegmans | |||
P2860 | cites work | LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice | Q35288337 |
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. | Q35780973 | ||
The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity | Q36154267 | ||
Brain Penetrant LRRK2 Inhibitor | Q36305876 | ||
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization | Q36780383 | ||
Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila | Q36891456 | ||
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease | Q37139305 | ||
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions | Q37225356 | ||
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants | Q39223630 | ||
Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition | Q39457004 | ||
Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. | Q54690286 | ||
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity | Q22254785 | ||
LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis | Q24299176 | ||
Kinase activity of mutant LRRK2 mediates neuronal toxicity | Q24303603 | ||
LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations | Q24306239 | ||
Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant | Q24306788 | ||
The familial Parkinsonism gene LRRK2 regulates neurite process morphology | Q24317613 | ||
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization | Q24339094 | ||
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling | Q28480459 | ||
Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation | Q28482925 | ||
Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease | Q28586694 | ||
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study | Q29614953 | ||
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin | Q29620478 | ||
Dynamic and redundant regulation of LRRK2 and LRRK1 expression | Q33307626 | ||
Identification of the autophosphorylation sites of LRRK2. | Q33510233 | ||
Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis | Q33595218 | ||
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease | Q34112588 | ||
Recent advances in the genetics of Parkinson's disease | Q34189660 | ||
P921 | main subject | ELISEA | Q332126 |
P1104 | number of pages | 10 | |
P304 | page(s) | 49-58 | |
P577 | publication date | 2012-12-16 | |
P1433 | published in | Journal of Pharmaceutical and Biomedical Analysis | Q15752537 |
P1476 | title | Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation | |
P478 | volume | 76 |
Q37053959 | Decoding Parkinson's Disease Pathogenesis: The Role of Deregulated mRNA Translation |
Q40188432 | In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2. |
Q42372493 | Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker |
Q47414771 | Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils |
Q96953324 | LRRK2 Phosphorylation, More Than an Epiphenomenon |
Q35170220 | Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955. |
Q39002226 | Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016). |
Q99238235 | Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics |
Q41163700 | Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation |
Q21131229 | Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism |
Q41579661 | Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells. |
Search more.